PIK3CA and neoplasm: Different aberrations in the PI3K signaling pathway, such as PI3K mutation/amplification, loss/mutation of the phosphatase and tensin homolog, Akt overexpression/overactivation, and modulation of tuberous sclerosis protein 1 and 2 tumor suppressors, can be often observed in HR+ breast cancers.